Mark W Tenforde, Zachary A Weber, Duck-Hye Yang, Malini B DeSilva, Kristin Dascomb, Stephanie A Irving, Allison L Naleway, Manjusha Gaglani, Bruce Fireman, Ned Lewis, Ousseny Zerbo, Kristin Goddard, Julius Timbol, John R Hansen, Nancy Grisel, Julie Arndorfer, Charlene E McEvoy, Inih J Essien, Suchitra Rao, Shaun J Grannis, Anupam B Kharbanda, Karthik Natarajan, Toan C Ong, Peter J Embi, Sarah W Ball, Margaret M Dunne, Lindsey Kirshner, Ryan E Wiegand, Monica Dickerson, Palak Patel, Caitlin Ray, Brendan Flannery, Shikha Garg, Katherine Adams, Nicola P Klein
{"title":"2022-2023 年美国成年人接种流感疫苗预防甲型流感相关急诊、紧急护理和住院治疗的效果。","authors":"Mark W Tenforde, Zachary A Weber, Duck-Hye Yang, Malini B DeSilva, Kristin Dascomb, Stephanie A Irving, Allison L Naleway, Manjusha Gaglani, Bruce Fireman, Ned Lewis, Ousseny Zerbo, Kristin Goddard, Julius Timbol, John R Hansen, Nancy Grisel, Julie Arndorfer, Charlene E McEvoy, Inih J Essien, Suchitra Rao, Shaun J Grannis, Anupam B Kharbanda, Karthik Natarajan, Toan C Ong, Peter J Embi, Sarah W Ball, Margaret M Dunne, Lindsey Kirshner, Ryan E Wiegand, Monica Dickerson, Palak Patel, Caitlin Ray, Brendan Flannery, Shikha Garg, Katherine Adams, Nicola P Klein","doi":"10.1093/infdis/jiad542","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The 2022-2023 United States influenza season had unusually early influenza activity with high hospitalization rates. Vaccine-matched A(H3N2) viruses predominated, with lower levels of A(H1N1)pdm09 activity also observed.</p><p><strong>Methods: </strong>Using the test-negative design, we evaluated influenza vaccine effectiveness (VE) during the 2022-2023 season against influenza A-associated emergency department/urgent care (ED/UC) visits and hospitalizations from October 2022 to March 2023 among adults (aged ≥18 years) with acute respiratory illness (ARI). VE was estimated by comparing odds of seasonal influenza vaccination among case-patients (influenza A test positive by molecular assay) and controls (influenza test negative), applying inverse-propensity-to-be-vaccinated weights.</p><p><strong>Results: </strong>The analysis included 85 389 ED/UC ARI encounters (17.0% influenza A positive; 37.8% vaccinated overall) and 19 751 hospitalizations (9.5% influenza A positive; 52.8% vaccinated overall). VE against influenza A-associated ED/UC encounters was 44% (95% confidence interval [CI], 40%-47%) overall and 45% and 41% among adults aged 18-64 and ≥65 years, respectively. VE against influenza A-associated hospitalizations was 35% (95% CI, 27%-43%) overall and 23% and 41% among adults aged 18-64 and ≥65 years, respectively.</p><p><strong>Conclusions: </strong>VE was moderate during the 2022-2023 influenza season, a season characterized with increased burden of influenza and co-circulation with other respiratory viruses. Vaccination is likely to substantially reduce morbidity, mortality, and strain on healthcare resources.</p>","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":5.0000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023.\",\"authors\":\"Mark W Tenforde, Zachary A Weber, Duck-Hye Yang, Malini B DeSilva, Kristin Dascomb, Stephanie A Irving, Allison L Naleway, Manjusha Gaglani, Bruce Fireman, Ned Lewis, Ousseny Zerbo, Kristin Goddard, Julius Timbol, John R Hansen, Nancy Grisel, Julie Arndorfer, Charlene E McEvoy, Inih J Essien, Suchitra Rao, Shaun J Grannis, Anupam B Kharbanda, Karthik Natarajan, Toan C Ong, Peter J Embi, Sarah W Ball, Margaret M Dunne, Lindsey Kirshner, Ryan E Wiegand, Monica Dickerson, Palak Patel, Caitlin Ray, Brendan Flannery, Shikha Garg, Katherine Adams, Nicola P Klein\",\"doi\":\"10.1093/infdis/jiad542\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The 2022-2023 United States influenza season had unusually early influenza activity with high hospitalization rates. Vaccine-matched A(H3N2) viruses predominated, with lower levels of A(H1N1)pdm09 activity also observed.</p><p><strong>Methods: </strong>Using the test-negative design, we evaluated influenza vaccine effectiveness (VE) during the 2022-2023 season against influenza A-associated emergency department/urgent care (ED/UC) visits and hospitalizations from October 2022 to March 2023 among adults (aged ≥18 years) with acute respiratory illness (ARI). VE was estimated by comparing odds of seasonal influenza vaccination among case-patients (influenza A test positive by molecular assay) and controls (influenza test negative), applying inverse-propensity-to-be-vaccinated weights.</p><p><strong>Results: </strong>The analysis included 85 389 ED/UC ARI encounters (17.0% influenza A positive; 37.8% vaccinated overall) and 19 751 hospitalizations (9.5% influenza A positive; 52.8% vaccinated overall). VE against influenza A-associated ED/UC encounters was 44% (95% confidence interval [CI], 40%-47%) overall and 45% and 41% among adults aged 18-64 and ≥65 years, respectively. VE against influenza A-associated hospitalizations was 35% (95% CI, 27%-43%) overall and 23% and 41% among adults aged 18-64 and ≥65 years, respectively.</p><p><strong>Conclusions: </strong>VE was moderate during the 2022-2023 influenza season, a season characterized with increased burden of influenza and co-circulation with other respiratory viruses. Vaccination is likely to substantially reduce morbidity, mortality, and strain on healthcare resources.</p>\",\"PeriodicalId\":50179,\"journal\":{\"name\":\"Journal of Infectious Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2024-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/infdis/jiad542\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/infdis/jiad542","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023.
Background: The 2022-2023 United States influenza season had unusually early influenza activity with high hospitalization rates. Vaccine-matched A(H3N2) viruses predominated, with lower levels of A(H1N1)pdm09 activity also observed.
Methods: Using the test-negative design, we evaluated influenza vaccine effectiveness (VE) during the 2022-2023 season against influenza A-associated emergency department/urgent care (ED/UC) visits and hospitalizations from October 2022 to March 2023 among adults (aged ≥18 years) with acute respiratory illness (ARI). VE was estimated by comparing odds of seasonal influenza vaccination among case-patients (influenza A test positive by molecular assay) and controls (influenza test negative), applying inverse-propensity-to-be-vaccinated weights.
Results: The analysis included 85 389 ED/UC ARI encounters (17.0% influenza A positive; 37.8% vaccinated overall) and 19 751 hospitalizations (9.5% influenza A positive; 52.8% vaccinated overall). VE against influenza A-associated ED/UC encounters was 44% (95% confidence interval [CI], 40%-47%) overall and 45% and 41% among adults aged 18-64 and ≥65 years, respectively. VE against influenza A-associated hospitalizations was 35% (95% CI, 27%-43%) overall and 23% and 41% among adults aged 18-64 and ≥65 years, respectively.
Conclusions: VE was moderate during the 2022-2023 influenza season, a season characterized with increased burden of influenza and co-circulation with other respiratory viruses. Vaccination is likely to substantially reduce morbidity, mortality, and strain on healthcare resources.
期刊介绍:
Published continuously since 1904, The Journal of Infectious Diseases (JID) is the premier global journal for original research on infectious diseases. The editors welcome Major Articles and Brief Reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses. JID is an official publication of the Infectious Diseases Society of America.